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Abstract
Swedish snus is a medium/high nicotine delivery, low-nitrosamine moist smokeless tobacco
product that has been estimated to be at least 90% less harmful than smoked tobacco. More men
use snus than smoke cigarettes in Sweden, and a quarter of male former smokers quit by switching
to snus. Leading multinational cigarette manufacturers have begun test-marketing snus-like
products in the United States and other countries. The version of Philip Morris' Marlboro snus
currently being marketed in the United States differs from Swedish snus in many ways; it has lower
moisture content and pH, but most puzzling is its very low nicotine delivery. Philip Morris, the
market-leader in United States cigarette sales, may have designed the product so that it does not
satisfy nicotine cravings and fails to enable smokers to switch. In this paper we compare and
contrast Swedish snus and Marlboro snus, and speculate as to why Philip Morris may have
intentionally designed a product that delivers very low levels of nicotine. We recommend that
Philip Morris cease using the term "snus" to refer to dry tobacco products with low nicotine
delivery, so that the term be reserved for moist, low-toxin, medium/high nicotine delivery
smokeless tobacco products that are qualitatively similar to the leading brands in Sweden.
1. Introduction
At the beginning of the twenty-first century, few tobacco
control advocates outside of Sweden had heard of "snus,"
the form of low-nitrosamine moist snuff tobacco that is
very popular in that country [1]. As of 2007, most of the
major multinational tobacco companies have begun test-
marketing their own brands of snus, using their leading
cigarette brand names to market new snus products (e.g.,
Camel snus, Lucky Strike snus, Peter Stuyvesant snus).
While increasing scientific evidence indicates that Swed-
ish snus is not harmless but is less harmful to health than
cigarettes [2-6], the public health community has
observed the launch of these new snus products outside of
Sweden with increasing apprehension [7-9].
Philip Morris USA (PM) started market testing its first
snus product, called Taboka, in Indianapolis in 2006.
Concern spiked when PM announced it would call its new
brand, Marlboro Snus. Along with Coca-Cola, Marlboro is
one of the top two "global megabrands" [10] and has
approximately 40% of the cigarette market in the United
States (U.S.). It would seem unlikely that the company
would place its leading brand name on a product that it
did not expect to succeed. However, data recently released
by PM raises questions about the company's intentions
and about the appropriateness of applying the term
"snus" to this product.
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the new PM smokeless tobacco product called Marlboro
Snus, and speculate as to why PM has intentionally
designed and marketed a smokeless tobacco product that
delivers relatively low levels of nicotine.
2. Discussion
What is Swedish Snus?
Swedish snus is an oral smokeless tobacco product that
typically contains approximately 50% moisture. Its rather
high pH (7.5–8.5) results in a high proportion of "free" or
unbound nicotine, which facilitates nicotine absorption
into the body [11]. A single 2 g dose of a leading brand of
Swedish snus is placed underneath the upper lip (reduc-
ing salivation) and gives the user a boost in blood nico-
tine concentration of around 15 ng/ml within 30 minutes
[12,13]. The relatively high nicotine delivery of Swedish
snus is similar to a cigarette, and much higher than most
existing nicotine replacement therapies including nicotine
gum, lozenge, inhaler and nasal spray. Notably, Swedish
snus is characterized by low concentrations of carcino-
genic tobacco-specific nitrosamines (TSNAs) and other
toxins relative to smokeless tobacco sold in the U.S.
[6,11]. It is believed that the relatively low levels of toxins
found in Swedish snus are due to the selection of air-cured
tobacco already low in toxins, and the use of a pasteuriza-
tion process which kills the microbes that otherwise con-
tribute to the formation of carcinogenic TSNAs [6,11].
Swedish snus is therefore a moist snuff product character-
ized by low TSNA concentration but high nicotine deliv-
ery. It is believed that the low toxin levels, combined with
the avoidance of smoke inhalation, are responsible for
Swedish snus being associated with substantially lower
health consequences than cigarette smoking [2-6]. Levy et
al. estimated that the median mortality relative risk for
low-nitrosamine smokeless tobacco was at least 90%
lower than for cigarette smoking [5]. Over one quarter of
male ex-smokers in Sweden reported they quit smoking
by switching to snus [14,15]; it is possible that the rela-
tively high nicotine delivery of Swedish snus makes the
transition from cigarettes to snus more comfortable
[14,16-20].
Industry data on Marlboro Snus and other new snus 
products
The Life Sciences Research Office Inc. (LSRO) is a non-
profit company located in Bethesda, Maryland USA. The
LSRO claims to "help our clients digest and assimi-
late...information and turn it to their advantage". LSRO
recently coordinated a series of meetings funded by PM
and attended by representatives from various tobacco
companies to discuss "Differentiating the Health Risks of
Categories of Tobacco Products". The agenda, presenta-
tions, and brief minutes of these meetings are available to
the public via the LSRO website and shed some light on
tobacco industry strategy on harm reduction.
Of particular interest was the recent presentation by
Michael T Fisher, PhD, of PM on "Snus smokeless tobacco
products" [21]. The presentation highlighted four main
differences between PM's new snus products and other
traditional moist oral smokeless tobacco sold in the U.S.
PM snus a) has a smaller portion size (0.23 g versus 1.5 g),
b) is pasteurized rather than fermented, c) utilizes "flavor-
film technology", and d) is dry, containing only 12%
moisture versus 50% for traditional moist snuff.
In addition, Fisher's presentation compared the chemical
constituents and 26 characteristics of 13 leading brands of
U.S. loose snuff, 3 leading brands of loose Swedish snus,
9 leading brands of portion-packed Swedish snus and one
brand of portion-packed U.S. snuff. Importantly, PM snus
has characteristically low concentrations of TSNAs similar
to Swedish snus. However, although PM snus contains a
similar amount of nicotine per weight as Swedish snus,
since its pH is below the bottom range for Swedish snus,
the amount of "free" nicotine that can be absorbed from
PM snus was well below the minimum of all the leading
brands of U.S. and Swedish smokeless tobacco products.
One slide in Fisher's presentation showed the blood nico-
tine levels found throughout the day in 26 subjects who
either smoked normally or used PM snus. While smoking,
these individuals had an afternoon blood nicotine con-
centration around 18 ng/ml (a relatively low concentra-
tion compared to other published data on afternoon
blood nicotine in smokers [22]), whereas the afternoon
level while using PM snus averaged under 4 ng/ml.
Fisher's data therefore reveal that PM snus, despite having
low concentrations of toxins like Swedish snus, is differ-
ent from its namesake in a number of important respects.
PM snus is dry rather than moist and, given its low pH,
delivers substantially lower levels of nicotine. Other dif-
ferences include the addition of a "flavor strip", much
smaller portion size, and manufacture in the U.S. rather
than Sweden. These differences lead us to question, is PM
Marlboro snus really snus at all? Of all the differences, the
most important and puzzling difference is the very low
nicotine delivery. Swedish snus has been perceived by
some as having a public health benefit in Sweden and
potentially in other countries by taking market share from
cigarettes [6,14,23]. The high nicotine delivery of Swedish
snus, which is similar to a cigarette, would appear to be
critical to that effect.
Why does Marlboro Snus deliver so little nicotine?
PM claims that their product design was based on an
assessment of consumer acceptability. But PM must be
aware that a tobacco product delivering minimal amountsPage 2 of 5
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ously tried to market an extremely low nicotine delivery
cigarette (Next) that predictably failed in the marketplace
(less than 0.2% market share) [24]. So why has PM cho-
sen to test market two snus products, one which is availa-
ble in four flavors, all with extremely low nicotine
delivery?
One possibility is that these initial products are being
tried in a few test markets simply to continue testing con-
sumer taste preferences, and that eventually the product
will evolve into a higher nicotine delivery product. Per-
haps these new products are intentionally being designed
as "graduation" products, from which starters will
progress to higher nicotine delivery products.
Another more Machiavellian possibility is that PM is per-
fectly aware that smokers will not use a low nicotine
smokeless product for long, just as auto manufacturers are
aware that there isn't a large market for safer cars with a
maximum speed of 30 miles per hour. In that case, we
have to assume that the test-marketing of PM snus is
intended to fail. What motive might PM have for such a
bizarre use of its most famous brand? PM has, by far, the
largest share of the U.S. cigarette market (50% including
all brands); thus a consumer switching from cigarettes to
smokeless is more likely to be leaving a PM cigarette
brand than a brand of their competitors. Furthermore, PM
has a high profit margin from its cigarettes that snus is
unlikely to replicate. Thus, even smokers who switch from
a PM cigarette brand to a PM snus brand will result in a
lower profit margin. It is therefore not in PM's financial
interest for snus to become as successful in the U.S. as it
has been in Sweden. One way to avoid this is to market a
product called snus without adequate delivery of the key
ingredient, nicotine. Mass marketing of this product could
potentially "vaccinate" U.S. smokers against switching to
snus by teaching them that snus is an unsatisfying product
with no nicotine "hit". Uniquely, PM is giving away cou-
pons for free Marlboro snus tins and is even attaching free
Marlboro snus samples to Marlboro cigarette packs.
Another motive may be perceived reduction of litigation
risks. If snus were to become as popular in the U.S. as it
has become among Swedish men (>50% of tobacco mar-
ket among men [6]), it could make it much harder to
defend smoking-caused lung-cancer law-suits, as it could
then be reasonably argued by victims' lawyers that PM is a
tobacco company that negligently and recklessly persisted
in selling a needlessly harmful product when it had good
evidence that it could stay in business selling a much less
harmful tobacco product that does not cause lung cancer
(i.e., snus). One way to avoid such an argument having
merit in court is to demonstrate that snus is not an accept-
able alternative to cigarettes in the U.S.
Issues around snus use as harm reduction in the U.S
Concerns about the introduction of Swedish snus in the
U.S. as a potential harm reduction product have been
expressed in both scientific journals [7-9] and popular
media [25], and center around two important issues. One
issue focuses on the possibility that introducing a new,
less harmful smokeless tobacco product will encourage
use by young people. There is little doubt that snus will be
used by young people just as cigarettes are. However, in
Sweden, snus use appears to be a pathway from smoking,
rather than being a gateway to smoking [14-17]. Further-
more, in northern Sweden, where snus use is most preva-
lent, only 3% of 25–34 year-old men are daily smokers,
while 34% are daily snus users [18]. Thus, it appears that
Swedish snus has replaced smoking for many young peo-
ple in Sweden. This is the very age-group with the highest
smoking prevalence in the United States who would have
a lot to gain by quitting smoking [26].
Perhaps the biggest threat to public health from new low
nitrosamine snus stems from the possibility that it may
foster persistent dual tobacco use instead of smoking ces-
sation. As restrictions on cigarette smoking increase,
smokers who might otherwise have quit may instead use
snus at times when they cannot smoke. A product deliver-
ing as little nicotine as PM snus will leave the smoker crav-
ing for a cigarette, possibly another part of PM's intention.
Although dual cigarette and snus use is not the pattern
emerging in Sweden [14,18], it is only recently that ciga-
rette companies have simultaneously been marketing
smokeless products in Sweden. Dual use of cigarettes and
snus is certainly a valid concern that needs to be moni-
tored closely.
3. Conclusion
Efforts to control tobacco-caused deaths and diseases con-
tinue to be hampered by inadequate regulatory control
over tobacco products. The Royal College of Physicians
(RCP) recently concluded that, "low nitrosamine smoke-
less tobacco products may have a positive role to play in a
coordinated and regulated harm reduction strategy which
maximizes public health benefit and protects against
commercial market exploitation," (p230) [11]. It is
unclear whether the form of FDA regulation currently pro-
posed for the United States, and supported by PM, would
embrace the model for tobacco harm reduction advocated
by the RCP.
Right now in the United States, tobacco manufacturers
can introduce new products, call them whatever they
wish, and change product ingredients without adequate
regulatory oversight or information for the public. It is
clear that the status quo is unacceptable and simply allows
the tobacco industry to confuse the public about the
nature of its products [27]. If Marlboro snus continues toPage 3 of 5
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appeal to smokers as an alternative to cigarettes, just as
PM's brand of cigarettes with very low nicotine delivery
(Next) was unsuccessful in the marketplace. It is possible
that PM intends for Marlboro snus to fail in the market-
place, and may even hope that the tobacco control lobby's
criticism of snus will assist with its demise [7,28,29]. Crit-
icism of snus by anti-tobacco groups may end up unwit-
tingly supporting PM's efforts to maintain the cigarette-
dominant status quo. In so doing, PM could prevent snus
from challenging the dominance of cigarettes – a product
that is at least ten times more harmful to health than snus
[5], and the number one cause of premature death in the
western world.
We recommend that PM cease using the term "snus" to
refer to dry smokeless tobacco products with low nicotine
delivery, so that the term be reserved for moist, low-toxin,
medium/high nicotine delivery smokeless tobacco prod-
ucts that are qualitatively similar to the leading brands in
Sweden.
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